Eli Lilly and Co Analyst Ratings
Morgan Stanley Maintains Overweight on Eli Lilly and Co, Maintains $1023 Price Target
Goldman Sachs raised the target price of Eli Lilly and Co. to $793.
BMO Capital Maintains Outperform on Eli Lilly and Co, Maintains $1001 Price Target
Goldman Sachs Adjusts Price Target on Eli Lilly & Co. to $793 From $785, Maintains Neutral Rating
Pfizer Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
Cantor Fitzgerald Reiterates Overweight on Eli Lilly and Co, Maintains $885 Price Target
Eli Lilly and Co Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price Target
Johnson & Johnson Analyst Ratings
Piper Sandler Maintains Neutral on Elanco Animal Health, Lowers Price Target to $16
Piper Sandler Sticks to Their Hold Rating for Elanco Animal Health (ELAN)
Barclays Raises Catalent's Price Target to $63 From $47, Maintains Equalweight Rating
Barclays Cuts Price Target on Elanco Animal Health to $21 From $23, Maintains Overweight Rating
Elanco Animal Health Analyst Ratings
Catalent Analyst Ratings
Barclays Adjusts Catalent Price Target to $63 From $47
Pfizer Analyst Ratings
Eli Lilly and Co Analyst Ratings